Screening of Extended Spectrum Beta Lactamase (ESBL) Producing Citrobacter freundii in Clinical and Animal Samples Isolated from Lagos, Nigeria
DOI:
https://doi.org/10.55006/biolsciences.2025.5203Keywords:
Beta-Lactamase, Citrobacter freundii, Extended spectrum, Antimicrobial Resistance, Antimicrobial SusceptibilityAbstract
The emergence in recent times of extended-spectrum beta-lactamases (ESBLs) producing pathogenic bacteria poses a serious antibiotic management problem. Citrobacter sp., though less commonly isolated are regarded as an emerging nosocomial multidrug-resistance (MDR) pathogen. The main objective of this study is to screen for ESBLs in Citrobacter freundii isolates. Over a period of two months, 50 clinical samples were collected from patients attending tertiary health institutions in Lagos state, and 45 animal samples were collected from cattle and poultry farms giving a total of 95 samples. The samples were cultured by standard procedures. Isolates were identified using standard methods. Antimicrobial susceptibility testing was performed on all isolates by Clinical and Laboratory Standards Institute (CLSI) guidelines. The isolates were further screened for ESBL production using double disk diffusion synergy techniques. 4 of the 48 Isolates were positive for Citrobacter freundii (8.33%). Other bacterial pathogens identified included Citrobacter koseri (14.58%), Escherichia coli (33.33%), E. coli O157 (10.42%), Klebsiella oxytoca (20.83%), Staphylococcus spp. (12.5%), and Pseudomonas aeruginosa (2.08%). Antimicrobial susceptibility testing revealed that high antibiotic resistance was observed in ceftazidime (100%), cefuroxime (100%), augmentin (100%), and low in ciprofloxacin (50%). Susceptibility was observed in gentamicin (100%), nitrofurantoin (100%), cefixime (75%) and ofloxacin (75%). None of the strains of Citrobacter freundii isolates showed ESBL production. Gentamicin and nitrofurantoin were found to be effective treatment option for Citrobacter freundii-associated infections. This study provides critical insights into antimicrobial resistance patterns, aiding in the development of better infection control strategies.
Downloads
References
1. Kalsi, J.M.; Arya, P.; Wilson, P.; Mundy, A. Hospital-acquired urinary tract infection. Int. J. Clin. Pract. 2003, 57, 388–391.
2. Rawat, D.; Nair, D. Extended-spectrum β-lactamases in Gram Negative Bacteria. J. Glob. Infect. Dis. 2010, 2(3), 263–274.
3. Pachori, P.; Gothalwal, R.; Gandhi, P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019, 6(2), 109–119.
4. Knothe, H.; Shah, P.; Krcmery, V.; Antal, M.; Mitsuhashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11(6), 315–317.
5. Philippon, A.; Labia, R.; Jacoby, G. Extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 1989, 33, 1131–1136.
6. Pitout, J.D.D.; Gregson, D.B.; Church, D.L.; Elsayed, S.; Laupland, K.V. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary health region. J. Clin. Microbiol. 2005, 43(6), 2844–2849.
7. Falagas, M.E.; Karageogopoulos, D.E. Extended-spectrum beta lactamases-producing organisms. J. Hosp. Infect. 2009, 73(4), 345–354.
8. RodrĂguez-Baño, J.; Pascual, A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev. Anti-Infect. Ther. 2008, 6(5), 671–683.
9. Baron, E.J.; Peterson, L.R.; Finegold, S.M. Bailey and Scott's Diagnostic Microbiology. Mosby: St. Louis, MO, 1994.
10. Winn, W.; Allen, S.; Janda, W.; Koneman, E.; Procop, G.; Schreckenberger, P. Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th ed. Lippincott Williams & Wilkins: Philadelphia, PA, 2006.
11. Forbes, B.A.; Sahm, D.F.; Weissfeld, A.S. Bailey and Scott's Diagnostic Microbiology, 12th ed. Mosby Elsevier: St. Louis, MO, 2007.
12. Greenwood, D.; Slack, R.C.B.; Barer, M.R.; Irving, W.L. Medical Microbiology, 18th ed. Elsevier Health Sciences, 2012.
13. Farmer, J.J. Enterobacteriaceae: Introduction and Identification. In Manual of Clinical Microbiology, 8th ed.; Murray, P.R., Baron, E.J., Jorgensen, J.H., Landry, M.L., Pfaller, M.A., Eds.; ASM Press: Washington, DC, 2003; pp. 649–669.
14. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI Document M100-S26. CLSI: Wayne, PA, 2016.
15. Jarlier, V.; Nicolas, M.H.; Fournier, G.; Philippon, A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 1988, 10(4), 867–878.
16. Paterson, D.L.; Bonomo, R.A. Extended-Spectrum β-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 2005, 18(4), 657–686.
17. Nandagopal, B.; et al. Frequency of extended spectrum β-lactamase producing urinary isolates of Gram-negative bacilli among patients seen in a multispecialty hospital in Vellore district, India. Indian J. Med. Microbiol. 2015, 33(2), 282–285.
18. Leski, T.A.; et al. High prevalence of multidrug resistant Enterobacteriaceae isolated from outpatient urine samples but not the hospital environment in Bo, Sierra Leone. BMC Infect. Dis. 2016, 16, 167.
19. Stoesser, N.; et al. Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus hospital-associated transmission in an endemic setting. Antimicrob. Agents Chemother. 2014, 58(12), 7347–7357.
20. Cantón, R. Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clin. Microbiol. Infect. 2009, 15(Suppl. 1), 20–25.
21. Cattoir, V.; Leclercq, R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J. Antimicrob. Chemother. 2013, 68(4), 731–742.
22. Ranjan, K.P.; Ranjan, N. Citrobacter: An emerging health care associated urinary pathogen. Urol. Ann. 2013, *5*(4), 313–314.
23. Majewski, P.; et al. Emergence of a multidrug-resistant Citrobacter freundii ST8 harboring an unusual VIM-4 gene cassette in Poland. Int. J. Infect. Dis. 2017, 61, 70–73.
24. Paterson, D.L.; Bonomo, R.A. Extended-Spectrum β-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 2005, *18*(4), 657–686.
25. Metri, B.C.; Jyothi, P.; Peerapur, B.V. Antibiotic resistance in Citrobacter spp. isolated from urinary tract infection. Urol. Ann. 2013, 5(4), 312–313.
26. Ahmed, T.; et al. Phenotypic and Genotypic Characteristics of Antimicrobial Resistance in Citrobacter freundii Isolated from Domestic Ducks (Anas platyrhynchos domesticus) in Bangladesh. Antibiotics 2023, 12(4), 769.
27. Arens, S.; Verbist, L. Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin. Microbiol. Infect. 1997, 3(1), 53–57.
28. Enoch, D.A.; et al. Epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae in a UK district hospital; an observational study. J. Hosp. Infect. 2012, 81(4), 270–277.
29. Al-Zarouni, M.; et al. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Med. Princ. Pract. 2008, 17(1), 32–36.
30. Sangare, S.A.; et al. Prevalence of ESBL-producing Enterobacteriaceae isolated from blood cultures in Mali. J. Infect. Dev. Ctries. 2016, 10(10), 1059–1064.
31. Søraas, A.; et al. Risk factors for community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae: a case-control study in a low prevalence country. PLoS One 2013, 8(7), e69581.
32. Amsalu, A.; et al. Antimicrobial resistance pattern of bacterial isolates from different clinical specimens in Southern Ethiopia: A three year retrospective study. J. Bacteriol. Res. 2017, 9(1), 1–8.
33. Prestinaci, F.; Pezzotti, P.; Pantosti, A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog. Glob. Health 2015, 109(7), 309–318.
34. Schwaber, M.J.; et al. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 2005, 49(5), 2137–2139.
35. Lukac, P.J.; Bonomo, R.A.; Logan, L.K. Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin. Infect. Dis. 2015, 60(9), 1389–1397.
36. Weiner, L.M.; et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect. Control Hosp. Epidemiol. 2016, 37(11), 1288–1301.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Zenas Chisom Agubata, Damilola Esther Sodunke, Ayodele Olubukola Olusola, Miriam Oluchi Ukhureigbe, Elizabeth Tomiwa Adesemoye, Felicia Ngozi Okoh
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
